---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-029517"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:31:11.606816+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Imunon reports Phase 2 OVATION 2 trial: 11.1-month OS increase in advanced ovarian cancer with IMNN-001

## Summary
- Median OS improved by 11.1 months (40.5 vs 29.4) in ITT; HR 0.74 (0.42-1.30).
- In patients receiving ≥3 doses, OS extended by 15.7 months (45.1 vs 29.4); HR 0.64.
- PARP inhibitor subgroup: median OS not reached in IMNN-001 arm vs 37.1 months; HR 0.41.
- PFS primary endpoint: 3-month improvement (14.9 vs 11.9); HR 0.79.
- Company plans registrational Phase 3 study to begin in Q1 2025; End-of-Phase 2 meeting with FDA.

## SEC filing metadata
- accession: 0001493152-24-029517
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315224029517/0001493152-24-029517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315224029517/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-029517
- JSON: https://secwatch.observer/filing/0001493152-24-029517.json
- Plain text: https://secwatch.observer/filing/0001493152-24-029517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.